Therapeutic effects of human amniotic mesenchymal stem cell-derived exosomes on stem cell proliferation in irradiated salivary glands via the Wnt pathway
Li ZZ., Zhang M., Wang X., Qi HZ., Wang YY., Cao JY.
Randomized Controlled Trial, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- Open Life Sci (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41726564
- PMCID
- PMC12917546
- DOI
- 10.1515/biol-2025-1277
Abstract (original English)
This study investigated the therapeutic potential of exosomes derived from human amniotic mesenchymal stem cells (hAMSCs-EXO) in enhancing stem cell proliferation and tissue regeneration in salivary glands following radiation-induced injury. 60 rats were randomly assigned to five experimental groups: (1) IR (irradiation followed by phosphate-buffered saline (PBS) injection), (2) XAV 939 (irradiation with subsequent administration of the Wnt signaling pathway inhibitor XAV-939), (3) XAV 939 + EXO (irradiation followed by hAMSCs-EXO and XAV-939), (4) EXO (irradiation followed by hAMSCs-EXO), and (5) Control (non-irradiated with PBS administration). Injections were administered on day 1 post-irradiation. Assessments included serial body weight, histopathology (H&E staining), immunofluorescence, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, stem cell marker expression, and proliferation analysis on days 1, 3, 7, and 14. The EXO group demonstrated notable preservation of salivary gland architecture and significantly increased expression of stem cell markers, relative to other irradiated groups, with marked effects observed by day 7. EdU and Ki67 immunostaining further indicated a significant enhancement in proliferative activity following hAMSCs-EXO treatment. In contrast, administration of XAV-939 alone was associated with reduced proliferation and diminished stem cell marker expr
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.